Current News

Contact | Print version | PDF version | Send article | RSS feed

Chemokine Therapeutics Announces Board Changes

23 Jul 2008 - Chemokine Therapeutics Corp. announced that Edward Taylor and Walter Korz have joined the Board of Directors. They will fill vacancies created by the resignations of Dr. Hassan Salari and Reza Bahadori. Dr. Salari has also resigned as the Company's part-time Chief Scientific Officer. Mr. Taylor will replace Dr. Salari as the Chairman of the Board.
 
Edward Taylor is a member of the Certified General Accountant's Association of Alberta and British Columbia. Mr. Taylor has been Vice President Finance and Administration and the Chief Financial Officer of Oncothyreon (formerly Biomira Inc.) since May 1995 where he has successfully raised over $300 million dollars through a variety of financing vehicles. He is a past Chairman of the British Columbia Institute of Technology and a graduate of the Stanford Executive Program. Mr. Taylor is Chairman of the Board of Ceapro Inc. and is a Director of two private biotechnology companies.
 
Walter Korz was appointed President and Chief Executive Officer in April 2008; prior to that he served as Vice President of Drug Development from April 2004. Prior to joining Chemokine Therapeutics he held the position of Clinical Development Manager with Angiotech Pharmaceutical. Mr. Korz's experience includes overseeing the development of diagnostic and therapeutic products for oncology with AltaRex. Mr. Korz received his Diploma in Hospital and Health Care Administration from the University of Saskatchewan and his Diploma in Nuclear Medicine from the Southern Alberta Institute of Technology. Recently Mr. Korz completed his Master of Business Administration from Athabasca University, Centre for Innovative Management.